The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Ropeginterferon Alfa-2b for Polycythemia Vera

Long-acting pegylated interferon for cytoreduction and molecular response

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Ropeginterferon Alfa-2b for Polycythemia Vera?

Ropeginterferon alfa-2b is a monopegylated proline-containing interferon with extended half-life supporting biweekly dosing.

Approved by the European Medicines Agency in 2019 and FDA in 2021 for adults with polycythemia vera.

Targets the malignant clone in addition to controlling counts, leading to JAK2 V617F allele burden reduction.

Long-term studies show maintained hematological response and progressive molecular response over years.

PROUD-PV/CONTINUATION-PV trials demonstrated superiority to hydroxyurea for molecular response and disease modification.

Symptoms

Symptoms of polycythemia vera: pruritus, headache, dizziness, plethora, splenomegaly.
Treatment-related: flu-like symptoms (fever, myalgia, fatigue) most common in first months.
Mood changes: depression, irritability, mood lability requiring monitoring.
Liver enzyme elevations and thyroid dysfunction during therapy.
Injection site reactions: erythema, pain, occasional induration.

Risk Factors

JAK2 V617F mutation positive (in greater than 95 percent of polycythemia vera patients).
Younger patients particularly suitable to avoid long-term hydroxyurea exposure.
Female of childbearing potential (avoids hydroxyurea teratogenicity).
History of mood disorders requires careful pretreatment evaluation.
Hepatic dysfunction or autoimmune disease at baseline.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent flu-like symptoms not improving over weeks of therapy.
  • New mood symptoms: depression, suicidal ideation, severe anxiety.
  • Worsening fatigue, jaundice, or signs of hepatic dysfunction.
  • Symptoms of thyroid dysfunction: weight changes, palpitations, cold intolerance.
  • Severe injection site reactions or systemic hypersensitivity.

Treatment Methods

01
Subcutaneous injection starting at 100 mcg every 2 weeks (50 mcg with hydroxyurea transition).
02
Dose escalation by 50 mcg every 2 weeks based on tolerance and response (maximum 500 mcg).
03
Biweekly to monthly dosing in maintenance once response achieved.
04
Phlebotomy adjunctively until hematocrit target (less than 45 percent) achieved.
05
Long-term follow-up with mental health screening, thyroid panel, and liver enzymes.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.